|
1
|
Brandes AA, Tosoni A, Franceschi E, Reni
M, Gatta G and Vecht C: Glioblastoma in adults. Crit Rev. Oncol
Hematol. 67:139–152. 2008.
|
|
2
|
Stupp R, Brada M, van den Bent MJ, Tonn JC
and Pentheroudakis G: High-grade glioma: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
25(Suppl 3): iii93–iii101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sanai N, Alvarez-Buylla A and Berger MS:
Neural stem cells and the origin of gliomas. N Engl J Med.
353:811–822. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yadav AK, Renfrow JJ, Scholtens DM, Xie H,
Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA,
et al: Monosomy of chromosome 10 associated with dysregulation of
epidermal growth factor signaling in glioblastomas. JAMA.
302:276–289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al European Organisation for Research and Treatment
of Cancer Brain Tumour and Radiation Oncology Groups: National
Cancer Institute of Canada Clinical Trials Group: Effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tanizaki Y, Sato Y, Oka H, Utsuki S, Kondo
K, Miyajima Y, Nagashio R and Fujii K: Expression of autocrine
motility factor mRNA is a poor prognostic factor in high-grade
astrocytoma. Pathol Int. 56:510–515. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Watanabe H, Takehana K, Date M, Shinozaki
T and Raz A: Tumor cell autocrine motility factor is the
neuroleukin/phosphohexose isomerase polypeptide. Cancer Res.
56:2960–2963. 1996.PubMed/NCBI
|
|
9
|
Niinaka Y, Paku S, Haga A, Watanabe H and
Raz A: Expression and secretion of neuroleukin/phosphohexose
isomerase/maturation factor as autocrine motility factor by tumor
cells. Cancer Res. 58:2667–2674. 1998.PubMed/NCBI
|
|
10
|
Haga A, Niinaka Y and Raz A: Phosphohexose
isomerase/autocrine motility factor/neuroleukin/maturation factor
is a multifunctional phosphoprotein. Biochim Biophys Acta.
1480:235–244. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shimizu K, Tani M, Watanabe H, Nagamachi
Y, Niinaka Y, Shiroishi T, Ohwada S, Raz A and Yokota J: The
autocrine motility factor receptor gene encodes a novel type of
seven transmembrane protein. FEBS Lett. 456:295–300. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Funasaka T, Haga A, Raz A and Nagase H:
Tumor autocrine motility factor is an angiogenic factor that
stimulates endothelial cell motility. Biochem Biophys Res Commun.
285:118–128. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Funasaka T, Haga A, Raz A and Nagase H:
Autocrine motility factor secreted by tumor cells upregulates
vascular endothelial growth factor receptor (Flt-1) expression in
endothelial cells. Int J Cancer. 101:217–223. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Funasaka T, Haga A, Raz A and Nagase H:
Tumor autocrine motility factor induces hyperpermeability of
endothelial and mesothelial cells leading to accumulation of
ascites fluid. Biochem Biophys Res Commun. 293:192–200. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haga A, Funasaka T, Niinaka Y, Raz A and
Nagase H: Autocrine motility factor signaling induces tumor
apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome
expression. Int J Cancer. 107:707–714. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Romagnoli A, Oliverio S, Evangelisti C,
Iannicola C, Ippolito G and Piacentini M: Neuroleukin inhibition
sensitises neuronal cells to caspase-dependent apoptosis. Biochem
Biophys Res Commun. 302:448–453. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsutsumi S, Hogan V, Nabi IR and Raz A:
Overexpression of the autocrine motility factor/phosphoglucose
isomerase induces transformation and survival of NIH-3T3
fibroblasts. Cancer Res. 63:242–249. 2003.PubMed/NCBI
|
|
18
|
Tsutsumi S, Yanagawa T, Shimura T,
Fukumori T, Hogan V, Kuwano H and Raz A: Regulation of cell
proliferation by autocrine motility factor/phosphoglucose isomerase
signaling. J Biol Chem. 278:32165–32172. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu FL, Liao MH, Lee JW and Shih WL:
Induction of hepatoma cells migration by phosphoglucose
isomerase/autocrine motility factor through the upregulation of
matrix metalloproteinase-3. Biochem Biophys Res Commun. 314:76–82.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Funasaka T, Hu H, Yanagawa T, Hogan V and
Raz A: Downregulation of phosphoglucose isomerase/autocrine
motility factor results in mesenchymal-to-epithelial transition of
human lung fibrosarcoma cells. Cancer Res. 67:4236–4243. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feuring-Buske M and Hogge DE: Hoechst
33342 efflux identifies a subpopulation of cytogenetically normal
CD34+CD38− progenitor cells from patients
with acute myeloid leukemia. Blood. 97:3882–3889. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim MC, D'Costa S, Suter S and Kim Y:
Evaluation of a side population of canine lymphoma cells using
Hoechst 33342 dye. J Vet Sci. 14:481–486. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Goodell MA, Brose K, Paradis G, Conner AS
and Mulligan RC: Isolation and functional properties of murine
hematopoietic stem cells that are replicating in vivo. J Exp Med.
183:1797–1806. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou S, Schuetz JD, Bunting KD, Colapietro
AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M,
Nakauchi H and Sorrentino BP: The ABC transporter Bcrp1/ABCG2 is
expressed in a wide variety of stem cells and is a molecular
determinant of the side-population phenotype. Nat Med. 7:1028–1034.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hirschmann-Jax C, Foster AE, Wulf GG,
Nuchtern JG, Jax TW, Gobel U, Goodell MA and Brenner MK: A distinct
'side population' of cells with high drug efflux capacity in human
tumor cells. Proc Natl Acad Sci USA. 101:14228–14233. 2004.
View Article : Google Scholar
|
|
26
|
Kondo T, Setoguchi T and Taga T:
Persistence of a small subpopulation of cancer stem-like cells in
the C6 glioma cell line. Proc Natl Acad Sci USA. 101:781–786. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wulf GG, Wang RY, Kuehnle I, Weidner D,
Marini F, Brenner MK, Andreeff M and Goodell MA: A leukemic stem
cell with intrinsic drug efflux capacity in acute myeloid leukemia.
Blood. 98:1166–1173. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vermeulen L, Sprick MR, Kemper K, Stassi G
and Medema JP: Cancer stem cells - old concepts, new insights. Cell
Death Differ. 15:947–958. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
30
|
Boumahdi S, Driessens G, Lapouge G, Rorive
S, Nassar D, Le Mercier M, Delatte B, Caauwe A, Lenglez S, Nkusi E,
et al: SOX2 controls tumour initiation and cancer stem-cell
functions in squamous-cell carcinoma. Nature. 511:246–250. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brafman DA, Moya N, Allen-Soltero S,
Fellner T, Robinson M, McMillen ZL, Gaasterland T and Willert K:
Analysis of SOX2-expressing cell populations derived from human
pluripotent stem cells. Stem Cell Rep. 1:464–478. 2013. View Article : Google Scholar
|
|
32
|
Bani-Yaghoub M, Tremblay RG, Lei JX, Zhang
D, Zurakowski B, Sandhu JK, Smith B, Ribecco-Lutkiewicz M, Kennedy
J, Walker PR, et al: Role of Sox2 in the development of the mouse
neocortex. Dev Biol. 295:52–66. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ferri AL, Cavallaro M, Braida D, Di
Cristofano A, Canta A, Vezzani A, Ottolenghi S, Pandolfi PP, Sala
M, DeBiasi S and Nicolis SK: Sox2 deficiency causes
neurodegeneration and impaired neurogenesis in the adult mouse
brain. Development. 131:3805–3819. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Graham V, Khudyakov J, Ellis P and Pevny
L: SOX2 functions to maintain neural progenitor identity. Neuron.
39:749–765. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Holland EC, Celestino J, Dai C, Schaefer
L, Sawaya RE and Fuller GN: Combined activation of Ras and Akt in
neural progenitors induces glioblastoma formation in mice. Nat
Genet. 25:55–57. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rajasekhar VK, Viale A, Socci ND, Wiedmann
M, Hu X and Holland EC: Oncogenic Ras and Akt signaling contribute
to glioblastoma formation by differential recruitment of existing
mRNAs to polysomes. Mol Cell. 12:889–901. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sonoda Y, Ozawa T, Aldape KD, Deen DF,
Berger MS and Pieper RO: Akt pathway activation converts anaplastic
astrocytoma to glioblastoma multiforme in a human astrocyte model
of glioma. Cancer Res. 61:6674–6678. 2001.PubMed/NCBI
|
